Proficio Capital Partners LLC Invests $535,000 in Insulet Corporation $PODD

Proficio Capital Partners LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 3,517 shares of the medical instruments supplier’s stock, valued at approximately $535,000.

Other large investors have also recently added to or reduced their stakes in the company. Corient Private Wealth LP purchased a new position in Insulet in the second quarter worth approximately $13,686,000. Ausdal Financial Partners Inc. purchased a new stake in Insulet in the second quarter valued at $206,000. Bank of America Corp DE acquired a new position in shares of Insulet in the 2nd quarter valued at $64,921,000. Strategic Global Advisors LLC acquired a new position in shares of Insulet in the 2nd quarter valued at $856,000. Finally, American Capital Management Inc. purchased a new position in shares of Insulet during the 2nd quarter worth $4,485,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Insulet Trading Up 0.0%

Shares of PODD stock opened at $143.41 on Friday. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a 50 day moving average price of $154.47 and a 200 day moving average price of $181.40. The stock has a market capitalization of $9.95 billion, a P/E ratio of 26.81, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the prior year, the business earned $1.17 EPS. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent analyst reports. Citigroup raised their price objective on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Canaccord Genuity Group decreased their target price on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Jefferies Financial Group lowered their target price on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Evercore set a $180.00 price target on shares of Insulet in a research report on Monday, July 6th. Finally, Stifel Nicolaus reduced their price target on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $195.40.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.